Is lorlatinib/lorlatinib a domestic or imported drug?

Lorlatinib is a targeted therapy drug mainly used to treat certain types of non-small cell lung cancer (NSCLC). The drug was developed by Pfizer and is currently sold in China under the brand name Lorbrena. Since its development and production are completed by international pharmaceutical companies, lorlatinib is classified as an imported drug.

The introduction of lorlatinib provides a new option for lung cancer treatment in China, especially when faced with patients who still progress after multiple therapies. Although domestic research and development of targeted drugs is increasing, as of now, there is no domestic version of lorlatinib on the market. This phenomenon reflects the complexity and challenges of targeted therapy drug research and development in specific fields in my country.

The import of lorlatinib gives it unique advantages in treatment. Its mechanism of action is to target EGFR and ALK mutations in lung cancer, and can effectively inhibit the proliferation and metastasis of tumor cells. Secondly, clinical trial results show that lorlatinib has shown good efficacy in treating patients with drug-resistant NSCLC, and some patients have even achieved long-term disease control. This makes lorlatinib an important option for many patients after traditional treatments fail.

While taking lorlatinib, patients need to follow their doctor's recommendations and undergo regular follow-up and monitoring. This not only helps to evaluate the effectiveness of treatment, but also to detect and deal with potential adverse reactions in a timely manner. Common side effects of lorlatinib include fatigue, loss of appetite, and gastrointestinal symptoms.

However, as an imported drug, the price of lorlatinib is relatively high, which may burden some patients with limited financial conditions. Currently, original research drugs marketed in China have been included in Class B medical insurance for reimbursement. Common specifications include 25mg*90 tablets and 100mg*30 tablets. The price of each box is about 20,000 yuan.